Age, high-risk disease, renal disease, and active or progressive disease were predictive of worse outcomes for patients with multiple myeloma and COVID-19.
Currently, interpretations of FDG-PET/CT findings within the context of treatment response have not been validated in the setting of multiple myeloma.
Intermittent dosing of the targeted agent may overcome toxicity limitations, providing a potential therapy for a hard-to-treat multiple myeloma.
In addition to age, sex, and comorbidities, a new study flagged uncontrolled cancer and renal insufficiency as key prognostic factors for COVID-19 outcomes.
Combination venetoclax, bortezomib, and dexamethasone may improve response rates among patients with relapsed/refractory MM with specific biomarkers.
A novel scoring system for patients with MM undergoing upfront autologous HSCT appears predictive of both progression-free survival and overall survival.
Adverse effect management and adherence strategies used to support patients with relapsed/refractory MM undergoing treatment on the STORM trial.
An analysis of outcomes for older patients with plasma cell myeloma suggests lenalidomide with bortezomib and dexamethasone is superior to doublet regimens.
Immunomodulatory imide drug (IMiD) therapy, including thalidomide and lenalidomide, has been associated with a high risk of VTE in patients with NDMM.
The triplet regimen resulted in an 18% reduction in risk for death.
The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.
Multiple myeloma trials appear to underrepresent racial minorities in enrollment and in reporting, with no obvious improvement in recent years.
The superiority of carfilzomib vs bortezomib in triplet therapy was compared in newly diagnosed multiple myeloma ineligible for immediate transplantation.
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
The cytogenetic abnormality was linked to inferior overall survival.
Patients with myeloma should receive 2 doses of the trivalent or quadrivalent vaccine influenza vaccine and vaccinations should continue annually.
The approval was based on data from the phase 3 CANDOR study and the phase 1b EQUULEUS trial.
Patients who relapsed 3 years or later after first transplant had significantly better progression-free and overall survival compared with those who relapsed earlier.
Increased odds of adverse outcomes seen for Hispanic/Latinos, African-American Blacks vs white patients.
A percentage of newly diagnosed patients had disease with lower genomic instability.
Oncopeptides will seek accelerated approval from the FDA after melflufen demonstrates a manageable safety profile.
The phase 3 IFM/DFCI 2009 trial investigators used WGS to determine genomic markers of long-term survival in patients with newly diagnosed MM.
The combination of carfilzomib, dexamethasone, and daratumumab significantly prolonged PFS in patients with relapsed or refractory multiple myeloma.
Patients with multiple myeloma on dialysis who are undergoing autologous stem cell transplantation are at an increased risk for inpatient mortality.
The FDA issued a clinical hold for a trial evaluating a universal CAR T-cell product in patients with relapsed or refractory multiple myeloma after 1 patient died.
MM cells expressing high levels of migration inhibitory factor may have poorer responses to proteasome inhibitors, resulting in adverse patient outcomes.
For patients with initial myeloma cast nephropathy, renal response rates did not significantly vary after doublet vs triplet bortezomib-based treatments.
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
Researchers presented initial results from an ongoing, phase 3, randomized study of once-weekly SVd vs twice-weekly Vd after 1 to 3 prior anti-multiple myeloma regimens.
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
Findings from this study support use of serial MRD monitoring during lenalidomide maintenance therapy to identify patients likely to benefit from prolonged treatment.
Researchers reported significant improvements in 5-year relative survival among older patients with multiple myeloma who were diagnosed from 1982 to 2017.
Higher graft CD34+ cell content is linked to improved platelet and neutrophil recovery after high-dose therapy.
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
Guidance is provided regarding possible treatment plan alterations for older patients with multiple myeloma based on COVID-19 infection risk.
Darzalex Faspro is a new subcutaneous formulation that contains daratumumab, a CD38-directed cytolytic antibody, with hyaluronidase, an endoglycosidase.
Differential effect seen by race, with significantly lower OS for white but not African-American patients.
Previous mostly retrospective/observational studies evaluated low-dose aspirin administered once daily in the setting of ET. In this study, the more frequent dosing was found optimal.
The SKY92 MMprofiler assay evaluates the expression of 92 multiple myeloma-related genes.
Investigators found that SC administration of daratumumab was noninferior to IV administration, and patient satisfaction appeared to be higher in the SC group.
An expanding range of treatment options in the past decade has led to greater long-term survival in patients with multiple myeloma.